(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced ...

An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer. John L. Marshall, ...

Three-year data from the Phase Ib trial of BOT+BAL was unveiled at ESMO GI 2026.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from ...

Additional SITC presentations cover 1) botensilimab's differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGFβ-trap bifunctional antibody Dhan Chand, PhD, Agenus' Head of Drug Discovery, to ...

Botensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust clinical activity in nine treatment-resistant tumor types, including microsatellite stable colorectal cancer ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation ...

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab. Patients with ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend ...

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial BOT was administered ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France's National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national ...